BioCentury | Nov 20, 2020
Deals

China in-licensing play LianBio follows $310M crossover round with broad Pfizer deal

Pfizer’s deal with LianBio will provide the Perceptive-backed, cross-border start-up with a commercial infrastructure in China, while giving the pharma a drug hunter and development partner led by veteran China biotech executives Bing Li and Debra...
BioCentury | Nov 14, 2020
Deals

Innovation in a hurry: China biotechs see a fast track to global stage – survey

The Chinese biopharma landscape in five years will see a majority of the money magnet companies commanding innovation, with first-in-class targets filling their pipelines and innovative biologics outpacing...
BioCentury | Nov 11, 2020
Product Development

As bemarituzumab data validate FGFR2b target in gastric cancers, Five Prime shares surge after hours

HER2-negative advanced gastric cancers may be one step closer to their first targeted therapy with positive efficacy data for Five Prime’s bemarituzumab. Shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX)...
BioCentury | Jun 4, 2020
Finance

Everest to fund late-stage trials with $310M mountain of fresh cash

A new $310 million series C round for Everest is the largest venture round yet for an Asian therapeutics developer, and could set the cross-border licensing and development company up for an IPO at a...
BioCentury | Apr 18, 2020
Regulation

Trio of approvals includes Seattle Genetics’ breast cancer therapy

Just two months after granting Priority Review to Seattle Genetics’ Tukysa tucatinib, FDA approved the drug as part of a triple combo to treat breast cancer, marking one of a trio of approvals Friday. Incyte...
BioCentury | Mar 10, 2020
Product Development

March 9 Quick Takes: A first for Boehringer’s Ofev; plus Cel-Sci’s COVID-19 therapy, Sinopharm, AZ, Urovant, Hengrui, Trevena, and Tetra-Shionogi

Boehringer’s Ofev approved as first therapy for lung scarring disease FDA approved Ofev nintedanib from Boehringer Ingelheim GmbH as the first therapy for chronic fibrosing interstitial lung diseases; the NDA had received Priority Review. The...
BioCentury | Jan 25, 2020
Emerging Company Profile

Aluda: targeting the fundamentals

Five years after its launch, Aluda is pulling back the curtain on its pipeline, leading with a first-in-class anti-VIM therapy for fibrotic indications. CEO Ruihuan Chen co-founded Aluda Pharmaceuticals Inc. in 2015 after 13 years...
BioCentury | Jan 24, 2020
Preclinical News

Jan. 23 Preclinical Quick Takes: Metastasis-associated cancer-associated fibroblast populations; plus NIH-TeneoBio and Basilea

Cancer-associated fibroblast subsets linked to metastasis In a study published in Nature Communications , a team from Institut Curie and INSERM identified within breast cancer patients’ lymph nodes four subpopulations of cancer-associated fibroblasts (CAFs). Two subsets...
BioCentury | Jan 22, 2020
Company News

Jan. 21 Company Quick Takes: First BCMA-targeted therapy gets Priority Review from FDA; plus Roche-Seattle Genetics, AZ-Merck, Chi-Med

Priority Review for GSK's anti-BCMA therapy in MM GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said FDA granted Priority Review to a BLA for belantamab mafodotin to treat fourth-line relapsed or refractory multiple myeloma in patients who have...
BioCentury | Jan 3, 2020
Clinical News

As itacitinib stumbles in acute GvHD, Incyte turns to chronic setting

Incyte’s discontinuation of itacitinib’s development in acute graft-versus-host disease after a Phase III miss has muddied the outlook for the JAK-1 inhibitor in the larger setting of chronic GvHD and marks a setback as the...
Items per page:
1 - 10 of 142